NFKB1 and breast cancer: Oral administration of epigallocatechin-3-gallate (EGCG) (400 mg capsules, three times daily) to BC patients undergoing radiotherapy showed that EGCG suppressed NF-κB expression and AKT phosphorylation in the patients’ serum.